Creative Planning boosted its holdings in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 11.7% during the first quarter, HoldingsChannel.com reports. The fund owned 128,976 shares of the biopharmaceutical company’s stock after purchasing an additional 13,500 shares during the period. Creative Planning’s holdings in Achillion Pharmaceuticals were worth $382,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. increased its position in Achillion Pharmaceuticals by 27.0% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 155,854 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 33,097 shares during the period. BlackRock Inc. increased its position in Achillion Pharmaceuticals by 1.5% during the 4th quarter. BlackRock Inc. now owns 12,101,177 shares of the biopharmaceutical company’s stock worth $19,241,000 after buying an additional 175,818 shares during the period. Meeder Asset Management Inc. increased its position in Achillion Pharmaceuticals by 107.3% during the 4th quarter. Meeder Asset Management Inc. now owns 26,476 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 13,706 shares during the period. Alps Advisors Inc. increased its position in Achillion Pharmaceuticals by 30.6% during the 4th quarter. Alps Advisors Inc. now owns 320,350 shares of the biopharmaceutical company’s stock worth $509,000 after buying an additional 75,105 shares during the period. Finally, Candriam Luxembourg S.C.A. increased its position in Achillion Pharmaceuticals by 11.5% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 725,000 shares of the biopharmaceutical company’s stock worth $1,153,000 after buying an additional 75,000 shares during the period. Institutional investors and hedge funds own 74.10% of the company’s stock.
Several research analysts have weighed in on ACHN shares. Barclays cut Achillion Pharmaceuticals from an “equal weight” rating to an “underweight” rating and lowered their price objective for the stock from $5.00 to $2.50 in a research report on Friday, May 3rd. Zacks Investment Research cut Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 15th. BidaskClub raised Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, February 22nd. Finally, William Blair reissued an “outperform” rating on shares of Achillion Pharmaceuticals in a report on Thursday, March 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $2.50.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). Research analysts anticipate that Achillion Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Achillion Pharmaceuticals, Inc. (ACHN) Shares Bought by Creative Planning” was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/achillion-pharmaceuticals-inc-achn-shares-bought-by-creative-planning.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
Further Reading: Can systematic risk be avoided?
Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.